Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

Abstract Background Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed
to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 …

Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous …

Background Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny
because of reports suggesting an increased cardiovascular risk associated with their use …

Background—Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal
adenomas but have been associated with increased cardiovascular risk. Methods and …

Background Overexpression of cyclooxygenase 2 (COX-2) has been associated with
colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition …

Background & Aims: In human and animal studies, nonsteroidal anti-inflammatory drugs
have been associated with a reduced risk of colorectal neoplasia. Although the underlying …

Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an
increased risk of thrombotic events, but only limited long-term data have been available for …

Reason for posting: Coxibs, the class of NSAIDs that selectively inhibit cyclooxygenase 2
(COX-2), were designed to reduce joint pain and inflammation without causing the gastric …

Colorectal cancer is the second leading cause of mortality in the United States. In the United
States, the cumulative lifetime risk of developing colorectal cancer for both men and women …